Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2021)

Historic Non Operating Investment Income for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Q1 2021 value amounting to $6.0 million.

  • Lineage Cell Therapeutics' Non Operating Investment Income rose 37885.53% to $6.0 million in Q1 2021 from the same period last year, while for Dec 2021 it was $6.0 million, marking a year-over-year increase of 3210.53%. This contributed to the annual value of $6.0 million for FY2021, which is 3210.53% up from last year.
  • As of Q1 2021, Lineage Cell Therapeutics' Non Operating Investment Income stood at $6.0 million, which was up 37885.53% from $712000.0 recorded in Q4 2020.
  • Over the past 5 years, Lineage Cell Therapeutics' Non Operating Investment Income peaked at $6.0 million during Q1 2021, and registered a low of -$4.5 million during Q3 2019.
  • Moreover, its 4-year median value for Non Operating Investment Income was $397000.0 (2018), whereas its average is $680307.7.
  • The largest annual percentage gain for Lineage Cell Therapeutics' Non Operating Investment Income in the last 5 years was 79813.95% (2019), contrasted with its biggest fall of 1948260.87% (2019).
  • Lineage Cell Therapeutics' Non Operating Investment Income (Quarter) stood at $523000.0 in 2018, then plummeted by 54.88% to $236000.0 in 2019, then skyrocketed by 201.69% to $712000.0 in 2020, then skyrocketed by 746.07% to $6.0 million in 2021.
  • Its Non Operating Investment Income stands at $6.0 million for Q1 2021, versus $712000.0 for Q4 2020 and $120000.0 for Q3 2020.